Novo Nordisk shares rally after Mash approval

FDA approval expands Wegovy use to treat Mash in adults with liver fibrosis, while Novo Nordisk trims profit outlook and faces competition

Novo Nordisk shares rally after Wegovy approved for Mash treatment

Novo Nordisk shares rose in Copenhagen after the US FDA approved semaglutide injections Wegovy and Ozempic for Mash in adults with liver fibrosis.
The decision opens a new growth path for the company as it seeks to diversify beyond weight loss and diabetes, but the stock had already moved in a volatile direction after a profit forecast cut last month.
The Mash label adds a potential revenue stream while the company navigates a tougher competitive landscape led by Eli Lilly and its Mounjaro product.

The approval signals a push to expand the use of a well known drug in a new disease category, which could help stabilize Novo Nordisk sales if payers cover the Mash treatment. However, investors will closely watch how quickly doctors adopt the therapy and how reimbursement will shape pricing.
Beyond the switch in uses, the bigger test is whether the company can translate regulatory wins into durable profits. The Mash indication comes as the weight loss market remains crowded and margins face scrutiny from investors and payers alike. The coming months will show if pipeline momentum and cost controls can offset competition.

Highlights

What matters next is how payers respond and whether Novo Nordisk can translate regulatory gains into steady earnings.